Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production
Authors
Keywords
-
Journal
MOLECULAR CARCINOGENESIS
Volume 56, Issue 5, Pages 1414-1426
Publisher
Wiley
Online
2016-12-20
DOI
10.1002/mc.22602
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Broad targeting of angiogenesis for cancer prevention and therapy
- (2015) Zongwei Wang et al. SEMINARS IN CANCER BIOLOGY
- EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma
- (2015) Lifang Yang et al. Oncotarget
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
- (2014) D Zhao et al. ONCOGENE
- A review of the current research on the role of bFGF and VEGF in angiogenesis
- (2014) M. Przybylski Journal of Wound Care
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
- (2013) Sampurna Chatterjee et al. JOURNAL OF CLINICAL INVESTIGATION
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
- (2013) Istvan Lang et al. LANCET ONCOLOGY
- Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway
- (2013) Q Deng et al. Cell Death & Disease
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
- (2011) V. Poindessous et al. CLINICAL CANCER RESEARCH
- Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
- (2011) Annette K. Larsen et al. PHARMACOLOGY & THERAPEUTICS
- Forty-Year Journey of Angiogenesis Translational Research
- (2011) Y. Cao et al. Science Translational Medicine
- Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway
- (2010) Y. Dong et al. CARCINOGENESIS
- Acetyl-11-Keto- -Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis
- (2009) X. Pang et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- The angiogenic switch in carcinogenesis
- (2009) Vanessa Baeriswyl et al. SEMINARS IN CANCER BIOLOGY
- Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling
- (2008) T. Yi et al. CANCER RESEARCH
- Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer
- (2008) Jasgit C. Sachdev et al. Clinical Breast Cancer
- Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways
- (2008) T. Yi et al. MOLECULAR CANCER THERAPEUTICS
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started